Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease. Issue 8 (13th May 2021)

• Record Type: Journal Article
• Authors: Marras, Connie; Mills, Kelly A.; Eberly, Shirley; Oakes, David; Chou, Kelvin L.; Halverson, Matthew; Parashos, Sotirios A.; Tarolli, Christopher G.; Lai, Jin‐Shei; Nowinsky, Cindy J.; Suchowersky, Oksana; Farbman, Eric S.; Shulman, Lisa M.; Simuni, Tanya
• Is Part Of: Movement disorders. Volume 36:Issue 8(2021)
• Page Start: 1979
• Page End: 1983
• Publication Date: 2021-05-13
• Subjects: quality of life -- measurement -- Parkinson's disease -- Neuro‐QoL; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.28641
• Languages: English
• ISSNs: 0885-3185

Abstract

ABSTRACT: Background: The Quality of Life in Neurological Disorders (Neuro‐QoL) is a publicly available health‐related quality‐of‐life measurement system. Objective: The aim of this study was to evaluate the utility of Neuro‐QoL item banks as outcome measures for clinical trials in Parkinson's disease. Methods: An analysis of Neuro‐QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort. Results: Among 310 participants over 3 years, changes in five of eight Neuro‐QoL domains were significant ( P < 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35–0.39). The largest effect size for change over the year in which levodopa was initiated was −0.19 for lower extremity function–mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group. Conclusions: More sensitive tools will be required to serve as an outcome measure in early Parkinson's disease. © 2021 International Parkinson and Movement Disorder Society